FDA investigating link between Parkinson’s drug Stalevo, heart disease

The U.S. Food and Drug Administration (FDA) has announced an investigation into whether the drug Stalevo, which is used to treat Parkinson’s disease, may increase elderly patients’ risk of heart attack and stroke.  The FDA encourages patients taking the drug to talk to their physicians about their risk of cardiovascular disease.

For the full story, go to the Los Angeles Times.

  • Get Answers Now

    Get a free case evaluation to help determine your legal rights.

  • Receive emails from Baron & Budd?
  • Receive text messages from Baron & Budd?
  • This field is for validation purposes and should be left unchanged.